 Satish Garg
Concepts (652)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 93 | 2023 | 1032 | 17.130 |
Why?
| | Diabetes Mellitus, Type 1 | 142 | 2023 | 3360 | 16.230 |
Why?
| | Blood Glucose Self-Monitoring | 67 | 2023 | 534 | 13.060 |
Why?
| | Blood Glucose | 107 | 2023 | 1939 | 12.770 |
Why?
| | Insulin | 79 | 2023 | 2162 | 10.720 |
Why?
| | Diabetes Mellitus, Type 2 | 55 | 2023 | 2174 | 9.510 |
Why?
| | Diabetes Mellitus | 30 | 2023 | 942 | 7.810 |
Why?
| | Hypoglycemia | 50 | 2023 | 400 | 7.620 |
Why?
| | Insulin Infusion Systems | 37 | 2022 | 304 | 5.640 |
Why?
| | Monitoring, Ambulatory | 17 | 2017 | 84 | 4.740 |
Why?
| | Myometrium | 9 | 2021 | 35 | 4.660 |
Why?
| | Buffaloes | 11 | 2021 | 12 | 4.630 |
Why?
| | Periodicals as Topic | 7 | 2020 | 191 | 3.580 |
Why?
| | Biosimilar Pharmaceuticals | 6 | 2020 | 25 | 3.440 |
Why?
| | Insulin Glargine | 25 | 2022 | 72 | 3.430 |
Why?
| | Hyperglycemia | 17 | 2022 | 312 | 3.430 |
Why?
| | Diabetic Ketoacidosis | 11 | 2022 | 168 | 3.280 |
Why?
| | Pregnancy in Diabetics | 13 | 2023 | 88 | 3.150 |
Why?
| | Uterine Contraction | 8 | 2021 | 16 | 3.130 |
Why?
| | Spermatozoa | 7 | 2021 | 91 | 3.020 |
Why?
| | Dog Diseases | 4 | 2021 | 44 | 2.870 |
Why?
| | Insulin Lispro | 14 | 2022 | 35 | 2.740 |
Why?
| | Insulin Aspart | 9 | 2020 | 26 | 2.680 |
Why?
| | Biomedical Technology | 5 | 2023 | 43 | 2.470 |
Why?
| | Insulin, Long-Acting | 21 | 2022 | 49 | 2.420 |
Why?
| | Glycosides | 9 | 2023 | 34 | 2.340 |
Why?
| | Cytokines | 7 | 2021 | 1900 | 2.300 |
Why?
| | Mercury | 3 | 2021 | 29 | 2.210 |
Why?
| | Humans | 196 | 2023 | 118972 | 2.070 |
Why?
| | Sperm Motility | 6 | 2021 | 28 | 1.920 |
Why?
| | Sperm Capacitation | 6 | 2021 | 12 | 1.840 |
Why?
| | Telemedicine | 6 | 2021 | 664 | 1.830 |
Why?
| | Plant Extracts | 5 | 2019 | 165 | 1.820 |
Why?
| | Antioxidants | 5 | 2020 | 564 | 1.670 |
Why?
| | Sepsis | 3 | 2023 | 531 | 1.560 |
Why?
| | Calcium | 8 | 2021 | 1169 | 1.530 |
Why?
| | Theileriasis | 2 | 2020 | 2 | 1.520 |
Why?
| | Female | 111 | 2023 | 61564 | 1.520 |
Why?
| | Mite Infestations | 2 | 2020 | 2 | 1.470 |
Why?
| | Animals | 50 | 2023 | 33381 | 1.470 |
Why?
| | Injections, Subcutaneous | 11 | 2021 | 138 | 1.450 |
Why?
| | Pancreas, Artificial | 4 | 2020 | 71 | 1.430 |
Why?
| | Adult | 80 | 2022 | 31512 | 1.420 |
Why?
| | rho-Associated Kinases | 3 | 2021 | 84 | 1.370 |
Why?
| | Male | 93 | 2022 | 57801 | 1.360 |
Why?
| | Calcium Signaling | 3 | 2021 | 219 | 1.360 |
Why?
| | Vasoconstriction | 2 | 2022 | 213 | 1.340 |
Why?
| | Postprandial Period | 5 | 2020 | 96 | 1.320 |
Why?
| | Trace Elements | 2 | 2020 | 46 | 1.280 |
Why?
| | Pre-Eclampsia | 10 | 2023 | 183 | 1.270 |
Why?
| | Cattle | 8 | 2020 | 978 | 1.260 |
Why?
| | Diabetes Complications | 5 | 2020 | 218 | 1.220 |
Why?
| | Drug Therapy, Combination | 14 | 2021 | 965 | 1.210 |
Why?
| | Trypanosomiasis | 2 | 2017 | 5 | 1.210 |
Why?
| | Insulin, Isophane | 6 | 2017 | 16 | 1.180 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 280 | 1.170 |
Why?
| | Rats, Wistar | 11 | 2020 | 399 | 1.160 |
Why?
| | Pandemics | 5 | 2022 | 1355 | 1.150 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 332 | 1.140 |
Why?
| | Drugs, Investigational | 2 | 2017 | 31 | 1.120 |
Why?
| | Protein Kinase C | 2 | 2018 | 297 | 1.080 |
Why?
| | Histamine | 2 | 2017 | 65 | 1.080 |
Why?
| | Middle Aged | 49 | 2022 | 27617 | 1.040 |
Why?
| | Lead | 2 | 2016 | 47 | 1.030 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 348 | 1.010 |
Why?
| | Coronavirus Infections | 2 | 2020 | 339 | 1.010 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 44 | 1.000 |
Why?
| | Uterus | 6 | 2021 | 194 | 0.970 |
Why?
| | Biomedical Research | 8 | 2017 | 612 | 0.960 |
Why?
| | Monitoring, Physiologic | 6 | 2023 | 271 | 0.930 |
Why?
| | Cross-Over Studies | 10 | 2020 | 456 | 0.910 |
Why?
| | Angiotensin II | 1 | 2023 | 107 | 0.880 |
Why?
| | Spleen | 3 | 2020 | 510 | 0.880 |
Why?
| | Dinoprost | 2 | 2021 | 31 | 0.860 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2013 | 103 | 0.860 |
Why?
| | Receptor, Notch3 | 1 | 2022 | 3 | 0.860 |
Why?
| | Sulfones | 2 | 2020 | 98 | 0.850 |
Why?
| | Benzamides | 2 | 2020 | 176 | 0.840 |
Why?
| | Aorta | 2 | 2022 | 367 | 0.840 |
Why?
| | Pregnancy | 23 | 2023 | 5690 | 0.840 |
Why?
| | Nifedipine | 6 | 2021 | 29 | 0.810 |
Why?
| | Arterial Pressure | 1 | 2022 | 99 | 0.800 |
Why?
| | Administration, Inhalation | 4 | 2018 | 656 | 0.800 |
Why?
| | Intermediate Filament Proteins | 1 | 2021 | 69 | 0.800 |
Why?
| | TRPC Cation Channels | 2 | 2021 | 11 | 0.790 |
Why?
| | Reproducibility of Results | 13 | 2022 | 2874 | 0.790 |
Why?
| | Calcium Channel Blockers | 6 | 2021 | 117 | 0.790 |
Why?
| | Type C Phospholipases | 2 | 2018 | 66 | 0.790 |
Why?
| | Dose-Response Relationship, Drug | 14 | 2020 | 1945 | 0.790 |
Why?
| | Dogs | 5 | 2021 | 371 | 0.790 |
Why?
| | Insulin Antibodies | 2 | 2020 | 101 | 0.780 |
Why?
| | Treatment Outcome | 20 | 2022 | 9342 | 0.780 |
Why?
| | Trypanosoma | 2 | 2017 | 6 | 0.780 |
Why?
| | Biopolymers | 1 | 2020 | 26 | 0.770 |
Why?
| | Gelatin | 1 | 2020 | 35 | 0.770 |
Why?
| | Mitochondrial Membranes | 1 | 2021 | 34 | 0.770 |
Why?
| | Endometritis | 2 | 2017 | 4 | 0.770 |
Why?
| | Theileria annulata | 1 | 2020 | 1 | 0.760 |
Why?
| | Chitosan | 1 | 2020 | 30 | 0.760 |
Why?
| | Copper Sulfate | 1 | 2020 | 6 | 0.760 |
Why?
| | Protein Precursors | 1 | 2021 | 126 | 0.750 |
Why?
| | Cattle Diseases | 1 | 2020 | 15 | 0.750 |
Why?
| | Selenium | 1 | 2020 | 38 | 0.750 |
Why?
| | Exophthalmos | 1 | 2020 | 19 | 0.750 |
Why?
| | Mutagens | 1 | 2020 | 17 | 0.750 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2017 | 12 | 0.750 |
Why?
| | Sulfonylurea Compounds | 2 | 2018 | 44 | 0.740 |
Why?
| | Diabetic Angiopathies | 6 | 2013 | 260 | 0.740 |
Why?
| | Calcium Channels | 2 | 2018 | 150 | 0.740 |
Why?
| | Betacoronavirus | 2 | 2020 | 254 | 0.730 |
Why?
| | Oleic Acid | 1 | 2020 | 34 | 0.730 |
Why?
| | Young Adult | 24 | 2022 | 10793 | 0.730 |
Why?
| | Patient Education as Topic | 6 | 2020 | 699 | 0.730 |
Why?
| | Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.730 |
Why?
| | Polyalthia | 1 | 2019 | 1 | 0.730 |
Why?
| | Mites | 1 | 2019 | 9 | 0.730 |
Why?
| | Newcastle disease virus | 1 | 2019 | 17 | 0.720 |
Why?
| | Infusions, Subcutaneous | 4 | 2016 | 19 | 0.720 |
Why?
| | Peroxidase | 2 | 2017 | 170 | 0.710 |
Why?
| | Isoproterenol | 1 | 2020 | 125 | 0.710 |
Why?
| | Signal Transduction | 5 | 2022 | 4709 | 0.710 |
Why?
| | Potassium Channels | 1 | 2020 | 123 | 0.700 |
Why?
| | Down-Regulation | 1 | 2022 | 627 | 0.690 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.690 |
Why?
| | Endocannabinoids | 2 | 2019 | 37 | 0.690 |
Why?
| | Uterine Artery | 1 | 2019 | 65 | 0.680 |
Why?
| | Oxidative Stress | 4 | 2020 | 1178 | 0.680 |
Why?
| | Aged | 24 | 2022 | 19657 | 0.670 |
Why?
| | Biosensing Techniques | 2 | 2018 | 107 | 0.670 |
Why?
| | Mercuric Chloride | 1 | 2018 | 3 | 0.660 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 14 | 0.660 |
Why?
| | Adolescent | 30 | 2022 | 18480 | 0.660 |
Why?
| | Wound Healing | 1 | 2020 | 270 | 0.650 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2017 | 4 | 0.640 |
Why?
| | Tocolysis | 1 | 2017 | 4 | 0.640 |
Why?
| | Eucalyptus | 1 | 2017 | 5 | 0.630 |
Why?
| | Ethanolamines | 1 | 2017 | 18 | 0.630 |
Why?
| | Glucose | 5 | 2022 | 953 | 0.630 |
Why?
| | Oxytocin | 2 | 2016 | 44 | 0.630 |
Why?
| | Vasodilation | 2 | 2019 | 457 | 0.630 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2018 | 50 | 0.630 |
Why?
| | KATP Channels | 1 | 2017 | 20 | 0.630 |
Why?
| | Norepinephrine | 1 | 2018 | 212 | 0.610 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 40 | 0.610 |
Why?
| | Self Care | 4 | 2013 | 357 | 0.610 |
Why?
| | Mitochondria | 2 | 2021 | 786 | 0.610 |
Why?
| | Immunoglobulin E | 1 | 2019 | 365 | 0.610 |
Why?
| | Interleukins | 1 | 2019 | 242 | 0.610 |
Why?
| | Insulins | 1 | 2018 | 34 | 0.610 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 576 | 0.600 |
Why?
| | Coinfection | 1 | 2018 | 119 | 0.600 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 907 | 0.600 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 4 | 0.600 |
Why?
| | Syringes | 3 | 2013 | 37 | 0.600 |
Why?
| | Cadmium | 1 | 2017 | 62 | 0.600 |
Why?
| | Therapies, Investigational | 1 | 2017 | 14 | 0.590 |
Why?
| | Minerals | 1 | 2016 | 39 | 0.580 |
Why?
| | Inflammation Mediators | 1 | 2020 | 502 | 0.580 |
Why?
| | Cholinesterases | 1 | 2016 | 6 | 0.580 |
Why?
| | Muscle Relaxation | 1 | 2016 | 32 | 0.570 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 98 | 0.560 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 110 | 0.560 |
Why?
| | Ambulatory Care Facilities | 2 | 2023 | 218 | 0.550 |
Why?
| | Consensus | 7 | 2023 | 534 | 0.550 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2016 | 144 | 0.540 |
Why?
| | Disposable Equipment | 2 | 2013 | 15 | 0.540 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 472 | 0.530 |
Why?
| | Vitamins | 1 | 2016 | 158 | 0.530 |
Why?
| | Drug Delivery Systems | 2 | 2018 | 306 | 0.520 |
Why?
| | Insulin Detemir | 5 | 2017 | 8 | 0.520 |
Why?
| | Gene Expression | 1 | 2020 | 1489 | 0.500 |
Why?
| | Rats | 7 | 2020 | 5392 | 0.500 |
Why?
| | Glucagon | 2 | 2022 | 97 | 0.490 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 736 | 0.480 |
Why?
| | Withania | 1 | 2013 | 3 | 0.480 |
Why?
| | Antiviral Agents | 1 | 2019 | 654 | 0.480 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2013 | 40 | 0.470 |
Why?
| | Double-Blind Method | 8 | 2022 | 1687 | 0.460 |
Why?
| | Extracellular Fluid | 1 | 2013 | 32 | 0.460 |
Why?
| | Glucosides | 3 | 2019 | 39 | 0.460 |
Why?
| | Weight Gain | 5 | 2018 | 493 | 0.460 |
Why?
| | Chlorpyrifos | 1 | 2013 | 6 | 0.450 |
Why?
| | Nervous System Diseases | 1 | 2016 | 261 | 0.450 |
Why?
| | Benzhydryl Compounds | 3 | 2019 | 60 | 0.450 |
Why?
| | History, 21st Century | 3 | 2020 | 170 | 0.450 |
Why?
| | Microsomes, Liver | 1 | 2013 | 59 | 0.450 |
Why?
| | Portal Vein | 1 | 2013 | 90 | 0.450 |
Why?
| | Arsenic | 1 | 2013 | 40 | 0.440 |
Why?
| | Myocardial Infarction | 1 | 2020 | 968 | 0.440 |
Why?
| | Time Factors | 12 | 2021 | 6412 | 0.430 |
Why?
| | Pyrazines | 1 | 2013 | 72 | 0.430 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 349 | 0.430 |
Why?
| | Ascorbic Acid | 1 | 2013 | 120 | 0.420 |
Why?
| | Prevalence | 8 | 2020 | 2326 | 0.410 |
Why?
| | Tocolytic Agents | 2 | 2017 | 16 | 0.410 |
Why?
| | Patient Preference | 1 | 2013 | 170 | 0.410 |
Why?
| | Triazoles | 1 | 2013 | 134 | 0.410 |
Why?
| | Biomarkers | 11 | 2023 | 3588 | 0.410 |
Why?
| | Needles | 1 | 2011 | 56 | 0.400 |
Why?
| | Goats | 2 | 2021 | 27 | 0.400 |
Why?
| | United States | 15 | 2021 | 12555 | 0.390 |
Why?
| | Clinical Trials as Topic | 7 | 2022 | 969 | 0.390 |
Why?
| | Registries | 5 | 2020 | 1810 | 0.390 |
Why?
| | Adrenergic beta-Agonists | 2 | 2017 | 132 | 0.380 |
Why?
| | History, 20th Century | 3 | 2019 | 281 | 0.380 |
Why?
| | Blood Chemical Analysis | 2 | 2017 | 95 | 0.370 |
Why?
| | Water Pollutants, Chemical | 1 | 2013 | 174 | 0.360 |
Why?
| | Acetylcholine | 3 | 2019 | 208 | 0.360 |
Why?
| | Calibration | 3 | 2018 | 135 | 0.350 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2022 | 165 | 0.350 |
Why?
| | China | 4 | 2020 | 175 | 0.350 |
Why?
| | Pregnancy Trimester, First | 3 | 2020 | 126 | 0.350 |
Why?
| | Intention to Treat Analysis | 3 | 2017 | 70 | 0.350 |
Why?
| | 4-Aminopyridine | 2 | 2020 | 21 | 0.350 |
Why?
| | Health Care Costs | 4 | 2016 | 394 | 0.340 |
Why?
| | Plant Leaves | 3 | 2019 | 118 | 0.340 |
Why?
| | Reference Values | 6 | 2023 | 774 | 0.340 |
Why?
| | Research Design | 6 | 2015 | 969 | 0.340 |
Why?
| | alpha-Tocopherol | 2 | 2020 | 24 | 0.330 |
Why?
| | Prediabetic State | 1 | 2011 | 234 | 0.330 |
Why?
| | Computer Systems | 2 | 2018 | 47 | 0.320 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1510 | 0.320 |
Why?
| | Software | 3 | 2013 | 613 | 0.320 |
Why?
| | Animals, Newborn | 2 | 2020 | 806 | 0.310 |
Why?
| | Veratridine | 2 | 2017 | 7 | 0.310 |
Why?
| | Prospective Studies | 12 | 2022 | 6471 | 0.300 |
Why?
| | Child | 11 | 2022 | 19129 | 0.300 |
Why?
| | Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.300 |
Why?
| | Equipment Design | 4 | 2010 | 519 | 0.290 |
Why?
| | United States Food and Drug Administration | 3 | 2018 | 175 | 0.290 |
Why?
| | Journal Impact Factor | 2 | 2020 | 28 | 0.280 |
Why?
| | Nitric Oxide | 3 | 2022 | 892 | 0.280 |
Why?
| | Exercise | 2 | 2014 | 1657 | 0.280 |
Why?
| | Vasodilator Agents | 2 | 2019 | 328 | 0.280 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 160 | 0.270 |
Why?
| | Ruthenium Red | 2 | 2016 | 9 | 0.270 |
Why?
| | Hypertension | 4 | 2011 | 1203 | 0.270 |
Why?
| | Albuminuria | 3 | 2017 | 195 | 0.270 |
Why?
| | Tissue Culture Techniques | 2 | 2017 | 67 | 0.270 |
Why?
| | Blotting, Western | 3 | 2017 | 1194 | 0.270 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1171 | 0.270 |
Why?
| | Lipoproteins | 2 | 2019 | 162 | 0.260 |
Why?
| | Copper | 2 | 2016 | 102 | 0.260 |
Why?
| | Phenylephrine | 2 | 2016 | 85 | 0.260 |
Why?
| | Fasting | 1 | 2006 | 264 | 0.260 |
Why?
| | Algorithms | 5 | 2018 | 1541 | 0.260 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 10 | 0.260 |
Why?
| | Body Weight | 7 | 2020 | 934 | 0.250 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 32 | 0.250 |
Why?
| | Mass Screening | 1 | 2011 | 1052 | 0.250 |
Why?
| | Pyrazoles | 2 | 2018 | 363 | 0.250 |
Why?
| | Phosphorylation | 2 | 2020 | 1633 | 0.250 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 1798 | 0.240 |
Why?
| | Calcinosis | 4 | 2010 | 282 | 0.240 |
Why?
| | Uridine Diphosphate | 1 | 2023 | 1 | 0.230 |
Why?
| | Dietary Supplements | 2 | 2018 | 467 | 0.230 |
Why?
| | Equipment Failure | 2 | 2018 | 114 | 0.220 |
Why?
| | Aged, 80 and over | 3 | 2022 | 6561 | 0.220 |
Why?
| | Endocrinology | 2 | 2016 | 68 | 0.220 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 23 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1244 | 0.220 |
Why?
| | Vitamin D-Binding Protein | 2 | 2020 | 14 | 0.220 |
Why?
| | Safety | 3 | 2009 | 304 | 0.210 |
Why?
| | Mice | 5 | 2023 | 15520 | 0.210 |
Why?
| | 3-Hydroxybutyric Acid | 2 | 2021 | 15 | 0.210 |
Why?
| | Mobile Applications | 2 | 2021 | 147 | 0.210 |
Why?
| | Ketosis | 1 | 2021 | 13 | 0.200 |
Why?
| | Child, Preschool | 5 | 2022 | 9491 | 0.200 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2019 | 56 | 0.200 |
Why?
| | Reference Standards | 4 | 2017 | 176 | 0.200 |
Why?
| | Illinois | 1 | 2021 | 38 | 0.200 |
Why?
| | Immunization, Passive | 1 | 2021 | 81 | 0.200 |
Why?
| | Los Angeles | 1 | 2021 | 60 | 0.200 |
Why?
| | Patient Isolation | 1 | 2021 | 19 | 0.200 |
Why?
| | New York City | 1 | 2021 | 75 | 0.200 |
Why?
| | Risk Factors | 7 | 2021 | 9000 | 0.190 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 55 | 0.190 |
Why?
| | Interleukin-13 | 1 | 2021 | 135 | 0.190 |
Why?
| | Patient Satisfaction | 3 | 2015 | 610 | 0.190 |
Why?
| | Micronucleus Tests | 1 | 2020 | 4 | 0.190 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3730 | 0.190 |
Why?
| | Comet Assay | 1 | 2020 | 15 | 0.190 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 1 | 0.190 |
Why?
| | Antigens, Viral | 1 | 2021 | 181 | 0.190 |
Why?
| | Progesterone | 2 | 2019 | 242 | 0.190 |
Why?
| | Incidence | 3 | 2017 | 2424 | 0.190 |
Why?
| | Uncoupling Protein 2 | 1 | 2020 | 6 | 0.190 |
Why?
| | Chromium | 1 | 2020 | 12 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1440 | 0.180 |
Why?
| | Cardiotoxicity | 1 | 2020 | 29 | 0.180 |
Why?
| | Income | 1 | 2021 | 173 | 0.180 |
Why?
| | Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.180 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 22 | 0.180 |
Why?
| | Curcumin | 1 | 2020 | 33 | 0.180 |
Why?
| | Cyclooxygenase 1 | 1 | 2019 | 22 | 0.180 |
Why?
| | Glycemic Index | 2 | 2009 | 24 | 0.180 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 8 | 0.180 |
Why?
| | Vero Cells | 1 | 2019 | 69 | 0.180 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 164 | 0.180 |
Why?
| | Virus Internalization | 1 | 2019 | 41 | 0.180 |
Why?
| | Lipid Peroxidation | 1 | 2020 | 156 | 0.180 |
Why?
| | Haptoglobins | 1 | 2019 | 49 | 0.180 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 283 | 0.170 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 245 | 0.170 |
Why?
| | Canagliflozin | 1 | 2019 | 11 | 0.170 |
Why?
| | Adamantane | 1 | 2019 | 16 | 0.170 |
Why?
| | Area Under Curve | 3 | 2015 | 296 | 0.170 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 110 | 0.170 |
Why?
| | Tyrosine | 1 | 2020 | 233 | 0.170 |
Why?
| | Immunity, Cellular | 2 | 2018 | 270 | 0.170 |
Why?
| | Dipeptides | 1 | 2019 | 51 | 0.170 |
Why?
| | Ion Channels | 1 | 2019 | 126 | 0.170 |
Why?
| | TRPV Cation Channels | 1 | 2019 | 32 | 0.170 |
Why?
| | California | 1 | 2020 | 382 | 0.170 |
Why?
| | Vitamin D | 2 | 2020 | 354 | 0.170 |
Why?
| | Congresses as Topic | 2 | 2020 | 204 | 0.170 |
Why?
| | Meals | 1 | 2020 | 101 | 0.170 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 28 | 0.160 |
Why?
| | Methyldopa | 1 | 2018 | 8 | 0.160 |
Why?
| | Patient Care Planning | 1 | 2019 | 143 | 0.160 |
Why?
| | Self Efficacy | 1 | 2002 | 366 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2009 | 1795 | 0.160 |
Why?
| | Aminooxyacetic Acid | 1 | 2017 | 1 | 0.160 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 149 | 0.160 |
Why?
| | Sodium Channel Agonists | 1 | 2017 | 1 | 0.160 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2017 | 3 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 667 | 0.160 |
Why?
| | International Agencies | 1 | 2017 | 29 | 0.160 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 28 | 0.160 |
Why?
| | Hemoglobin A | 1 | 2017 | 22 | 0.160 |
Why?
| | Malondialdehyde | 1 | 2017 | 30 | 0.160 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.160 |
Why?
| | Administration, Oral | 2 | 2017 | 756 | 0.160 |
Why?
| | Injections | 1 | 2018 | 167 | 0.160 |
Why?
| | Equivalence Trials as Topic | 1 | 2017 | 6 | 0.160 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 683 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 527 | 0.160 |
Why?
| | Methanol | 1 | 2017 | 35 | 0.160 |
Why?
| | Glyburide | 1 | 2017 | 36 | 0.160 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 30 | 0.160 |
Why?
| | Antibodies, Viral | 1 | 2021 | 542 | 0.150 |
Why?
| | Alkynes | 1 | 2017 | 56 | 0.150 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 73 | 0.150 |
Why?
| | DNA Damage | 1 | 2020 | 357 | 0.150 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2513 | 0.150 |
Why?
| | Protein Carbonylation | 1 | 2017 | 52 | 0.150 |
Why?
| | Analysis of Variance | 1 | 2020 | 1293 | 0.150 |
Why?
| | Blood Pressure | 3 | 2021 | 1664 | 0.150 |
Why?
| | Adipokines | 1 | 2017 | 46 | 0.150 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 336 | 0.150 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 176 | 0.150 |
Why?
| | Phytotherapy | 1 | 2017 | 69 | 0.150 |
Why?
| | Patient Compliance | 2 | 2013 | 537 | 0.150 |
Why?
| | Patient Dropouts | 1 | 2017 | 66 | 0.150 |
Why?
| | Solvents | 1 | 2017 | 118 | 0.150 |
Why?
| | Propanolamines | 1 | 2017 | 93 | 0.150 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2013 | 47 | 0.150 |
Why?
| | Clinical Protocols | 1 | 2018 | 238 | 0.150 |
Why?
| | Anniversaries and Special Events | 1 | 2017 | 13 | 0.150 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 168 | 0.150 |
Why?
| | Antigen Presentation | 1 | 2018 | 194 | 0.150 |
Why?
| | Glycine | 1 | 2017 | 162 | 0.150 |
Why?
| | Piperidines | 1 | 2018 | 171 | 0.150 |
Why?
| | Immunization | 1 | 2019 | 412 | 0.150 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 167 | 0.150 |
Why?
| | Computer-Aided Design | 1 | 2017 | 42 | 0.150 |
Why?
| | Furans | 1 | 2016 | 23 | 0.150 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 437 | 0.150 |
Why?
| | Pilot Projects | 2 | 2018 | 1419 | 0.150 |
Why?
| | Coronary Artery Disease | 3 | 2010 | 647 | 0.150 |
Why?
| | Indicators and Reagents | 1 | 2016 | 100 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1129 | 0.150 |
Why?
| | Oleaceae | 1 | 2016 | 2 | 0.150 |
Why?
| | Cell Survival | 1 | 2020 | 1047 | 0.140 |
Why?
| | Lung | 1 | 2009 | 3664 | 0.140 |
Why?
| | Aniline Compounds | 1 | 2016 | 71 | 0.140 |
Why?
| | Antibody Formation | 1 | 2018 | 276 | 0.140 |
Why?
| | Cysteine | 1 | 2017 | 184 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1166 | 0.140 |
Why?
| | Sympathomimetics | 1 | 2016 | 26 | 0.140 |
Why?
| | In Vitro Techniques | 2 | 2016 | 1094 | 0.140 |
Why?
| | Up-Regulation | 1 | 2020 | 872 | 0.140 |
Why?
| | Eating | 3 | 2009 | 369 | 0.140 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 83 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 465 | 0.140 |
Why?
| | Estradiol | 1 | 2019 | 476 | 0.140 |
Why?
| | Comorbidity | 1 | 2021 | 1527 | 0.140 |
Why?
| | Leptin | 2 | 2017 | 231 | 0.140 |
Why?
| | Membrane Potentials | 1 | 2016 | 253 | 0.140 |
Why?
| | Testis | 1 | 2016 | 144 | 0.140 |
Why?
| | Amyloid | 2 | 2007 | 87 | 0.140 |
Why?
| | Moringa oleifera | 1 | 2015 | 1 | 0.140 |
Why?
| | Forecasting | 2 | 2016 | 353 | 0.140 |
Why?
| | Drug Design | 1 | 2017 | 160 | 0.140 |
Why?
| | Incretins | 1 | 2015 | 15 | 0.140 |
Why?
| | Vascular Stiffness | 1 | 2021 | 425 | 0.140 |
Why?
| | Postnatal Care | 1 | 2016 | 68 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2017 | 306 | 0.130 |
Why?
| | Imidazoles | 1 | 2016 | 232 | 0.130 |
Why?
| | RNA, Messenger | 1 | 2023 | 2657 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 290 | 0.130 |
Why?
| | Body Mass Index | 5 | 2017 | 2092 | 0.130 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 256 | 0.130 |
Why?
| | Early Diagnosis | 2 | 2015 | 230 | 0.130 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 330 | 0.130 |
Why?
| | Self-Management | 1 | 2017 | 136 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 354 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 571 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2020 | 4077 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2018 | 289 | 0.120 |
Why?
| | Estrenes | 1 | 2014 | 15 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2019 | 3171 | 0.120 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 198 | 0.120 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 162 | 0.120 |
Why?
| | Materials Testing | 2 | 2017 | 359 | 0.120 |
Why?
| | Pyrrolidinones | 1 | 2014 | 25 | 0.120 |
Why?
| | Organometallic Compounds | 1 | 2015 | 88 | 0.120 |
Why?
| | Colorado | 2 | 2020 | 4196 | 0.120 |
Why?
| | Inflammation | 1 | 2005 | 2566 | 0.120 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.120 |
Why?
| | Quality of Life | 5 | 2016 | 2366 | 0.120 |
Why?
| | Allylamine | 1 | 2013 | 7 | 0.120 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 394 | 0.120 |
Why?
| | Bromocriptine | 1 | 2013 | 28 | 0.120 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 21 | 0.120 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 86 | 0.120 |
Why?
| | Leadership | 1 | 2017 | 311 | 0.120 |
Why?
| | Prenatal Care | 1 | 2016 | 252 | 0.120 |
Why?
| | Staining and Labeling | 1 | 2014 | 146 | 0.120 |
Why?
| | Catecholamines | 1 | 2013 | 100 | 0.120 |
Why?
| | Escherichia coli | 1 | 2017 | 758 | 0.120 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 940 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1691 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 2995 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2015 | 225 | 0.110 |
Why?
| | Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 101 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2016 | 408 | 0.110 |
Why?
| | Coronary Disease | 2 | 2007 | 356 | 0.110 |
Why?
| | Autoantibodies | 2 | 2018 | 1335 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2017 | 439 | 0.110 |
Why?
| | Menopause | 1 | 2016 | 266 | 0.110 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 30 | 0.110 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1774 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 827 | 0.110 |
Why?
| | Circadian Rhythm | 4 | 2015 | 401 | 0.110 |
Why?
| | Insecticides | 1 | 2013 | 31 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 161 | 0.110 |
Why?
| | Patient Selection | 2 | 2009 | 676 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2013 | 68 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2013 | 146 | 0.110 |
Why?
| | Zinc | 1 | 2015 | 262 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2445 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2016 | 2275 | 0.100 |
Why?
| | Drinking Water | 1 | 2013 | 68 | 0.100 |
Why?
| | Internet | 1 | 2016 | 633 | 0.100 |
Why?
| | Self Administration | 1 | 2011 | 125 | 0.100 |
Why?
| | Carotenoids | 1 | 2011 | 35 | 0.100 |
Why?
| | Hospitalization | 1 | 2020 | 1785 | 0.100 |
Why?
| | Swine | 1 | 2013 | 730 | 0.100 |
Why?
| | Managed Care Programs | 1 | 2011 | 135 | 0.100 |
Why?
| | Cohort Studies | 4 | 2019 | 5116 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2020 | 12978 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 4708 | 0.090 |
Why?
| | Home Care Services | 1 | 2013 | 217 | 0.090 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 28 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 304 | 0.090 |
Why?
| | Regression Analysis | 2 | 2010 | 983 | 0.090 |
Why?
| | Metformin | 1 | 2013 | 295 | 0.090 |
Why?
| | Drug Combinations | 1 | 2010 | 291 | 0.090 |
Why?
| | Decision Making | 2 | 2013 | 809 | 0.090 |
Why?
| | Physicians | 2 | 2017 | 794 | 0.080 |
Why?
| | Carcinogens | 1 | 2009 | 108 | 0.080 |
Why?
| | Disease Progression | 3 | 2012 | 2490 | 0.080 |
Why?
| | Vital Capacity | 1 | 2009 | 260 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2015 | 4552 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 681 | 0.080 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 36 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2013 | 360 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2478 | 0.080 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 520 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| | Norway | 2 | 2019 | 35 | 0.080 |
Why?
| | Drug Costs | 1 | 2008 | 94 | 0.080 |
Why?
| | Sheep | 1 | 2010 | 764 | 0.080 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 57 | 0.080 |
Why?
| | Infusion Pumps, Implantable | 2 | 2004 | 20 | 0.080 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 82 | 0.070 |
Why?
| | Australia | 2 | 2019 | 212 | 0.070 |
Why?
| | Medication Adherence | 1 | 2011 | 556 | 0.070 |
Why?
| | Infant | 1 | 2020 | 8293 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 82 | 0.070 |
Why?
| | Societies, Medical | 1 | 2010 | 703 | 0.070 |
Why?
| | Risk Management | 2 | 2019 | 90 | 0.070 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 195 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 687 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 992 | 0.070 |
Why?
| | Creatinine | 2 | 2018 | 491 | 0.070 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.070 |
Why?
| | Immunity, Humoral | 2 | 2016 | 117 | 0.060 |
Why?
| | Barium Compounds | 1 | 2004 | 7 | 0.060 |
Why?
| | Terbutaline | 1 | 2004 | 9 | 0.060 |
Why?
| | Organ Size | 2 | 2016 | 460 | 0.060 |
Why?
| | Potassium Chloride | 1 | 2004 | 41 | 0.060 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2004 | 19 | 0.060 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2004 | 44 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 193 | 0.060 |
Why?
| | Automation | 1 | 2004 | 77 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2005 | 128 | 0.060 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 683 | 0.060 |
Why?
| | Albuterol | 1 | 2004 | 104 | 0.060 |
Why?
| | Capillaries | 1 | 2004 | 103 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1063 | 0.060 |
Why?
| | Chlorides | 1 | 2004 | 137 | 0.060 |
Why?
| | Homeostasis | 1 | 2007 | 594 | 0.060 |
Why?
| | Modems | 1 | 2003 | 1 | 0.060 |
Why?
| | Glycation End Products, Advanced | 1 | 2023 | 67 | 0.060 |
Why?
| | Primary Health Care | 1 | 2013 | 1560 | 0.060 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 55 | 0.060 |
Why?
| | Transaminases | 1 | 2022 | 26 | 0.060 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 74 | 0.050 |
Why?
| | Food | 1 | 2004 | 162 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 32 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 202 | 0.050 |
Why?
| | Educational Status | 1 | 2004 | 437 | 0.050 |
Why?
| | Pregnant Women | 1 | 2023 | 132 | 0.050 |
Why?
| | Weight Loss | 2 | 2018 | 655 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 138 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4596 | 0.050 |
Why?
| | Ketone Bodies | 1 | 2021 | 17 | 0.050 |
Why?
| | Prognosis | 2 | 2020 | 3443 | 0.050 |
Why?
| | Brain | 1 | 2013 | 2490 | 0.050 |
Why?
| | Preconception Care | 1 | 2002 | 28 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2002 | 53 | 0.050 |
Why?
| | Age of Onset | 1 | 2003 | 467 | 0.050 |
Why?
| | Breath Tests | 1 | 2021 | 89 | 0.050 |
Why?
| | Ketones | 1 | 2021 | 45 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 387 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 78 | 0.050 |
Why?
| | Pregnancy Trimester, Second | 1 | 2020 | 70 | 0.050 |
Why?
| | Gestational Age | 1 | 2003 | 765 | 0.050 |
Why?
| | Learning | 1 | 2004 | 374 | 0.050 |
Why?
| | Self Concept | 1 | 2002 | 215 | 0.050 |
Why?
| | Birth Weight | 1 | 2003 | 465 | 0.050 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2020 | 35 | 0.050 |
Why?
| | Skin | 1 | 2004 | 657 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 356 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 271 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1231 | 0.040 |
Why?
| | Acrosome Reaction | 1 | 2019 | 2 | 0.040 |
Why?
| | Polyunsaturated Alkamides | 1 | 2019 | 8 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 56 | 0.040 |
Why?
| | Capsaicin | 1 | 2019 | 26 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2019 | 57 | 0.040 |
Why?
| | Sleep | 2 | 2015 | 660 | 0.040 |
Why?
| | Immunoblotting | 1 | 2019 | 307 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 152 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 33 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 253 | 0.040 |
Why?
| | Sodium | 1 | 2019 | 200 | 0.040 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2017 | 5 | 0.040 |
Why?
| | Resistin | 1 | 2017 | 13 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 185 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2017 | 64 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1720 | 0.040 |
Why?
| | North America | 1 | 2018 | 266 | 0.040 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 62 | 0.040 |
Why?
| | Lost to Follow-Up | 1 | 2017 | 21 | 0.040 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 10 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 653 | 0.040 |
Why?
| | Semen | 1 | 2016 | 18 | 0.040 |
Why?
| | Hypersensitivity, Delayed | 1 | 2016 | 52 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 536 | 0.040 |
Why?
| | Drug Resistance | 1 | 2017 | 167 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 574 | 0.040 |
Why?
| | Models, Economic | 1 | 2016 | 48 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 77 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 158 | 0.030 |
Why?
| | Edema | 1 | 2016 | 124 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 490 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1353 | 0.030 |
Why?
| | Flowers | 1 | 2016 | 56 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 187 | 0.030 |
Why?
| | Adiponectin | 1 | 2017 | 226 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2016 | 126 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 642 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 39 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2015 | 135 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2179 | 0.030 |
Why?
| | Body Burden | 1 | 2015 | 5 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 137 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 416 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 2016 | 174 | 0.030 |
Why?
| | Communication | 1 | 2020 | 761 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2020 | 781 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2017 | 354 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 422 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1816 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 829 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2015 | 168 | 0.030 |
Why?
| | Genotype | 2 | 2010 | 1882 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 554 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 867 | 0.030 |
Why?
| | Data Display | 1 | 2013 | 22 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 827 | 0.030 |
Why?
| | E-Selectin | 1 | 2013 | 52 | 0.030 |
Why?
| | Testosterone | 1 | 2016 | 351 | 0.030 |
Why?
| | Chemokine CXCL10 | 1 | 2013 | 40 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2025 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2016 | 688 | 0.030 |
Why?
| | Risk | 1 | 2015 | 853 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2013 | 307 | 0.030 |
Why?
| | Bone and Bones | 1 | 2015 | 289 | 0.030 |
Why?
| | Tetraethylammonium | 1 | 2011 | 15 | 0.030 |
Why?
| | beta Carotene | 1 | 2011 | 17 | 0.030 |
Why?
| | Phenotype | 1 | 2019 | 3003 | 0.020 |
Why?
| | Vitamin A | 1 | 2011 | 55 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 56 | 0.020 |
Why?
| | Calcium Chloride | 1 | 2010 | 15 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 770 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2010 | 31 | 0.020 |
Why?
| | Expert Testimony | 1 | 2010 | 56 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 373 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2011 | 140 | 0.020 |
Why?
| | Nitrites | 1 | 2010 | 81 | 0.020 |
Why?
| | Intracellular Space | 1 | 2010 | 69 | 0.020 |
Why?
| | Extracellular Space | 1 | 2010 | 127 | 0.020 |
Why?
| | Potassium | 1 | 2010 | 132 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 122 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 225 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2674 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 982 | 0.020 |
Why?
| | Serotonin | 1 | 2010 | 309 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 11 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 74 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 407 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 88 | 0.020 |
Why?
| | Peptides | 1 | 2011 | 879 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1868 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1715 | 0.020 |
Why?
| | Fructosamine | 1 | 2005 | 21 | 0.020 |
Why?
| | Hemoglobins | 1 | 2007 | 326 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 362 | 0.020 |
Why?
| | Sex Distribution | 1 | 2005 | 351 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2436 | 0.010 |
Why?
| | Hemoglobinuria | 1 | 2003 | 5 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2003 | 671 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 1901 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1180 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|